Everolimus and Pentacarinat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Everolimus (everolimus) and Pentacarinat (pentamidine isethionate). Common drug interactions include immunosuppressant drug level increased among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Everolimus and Pentacarinat. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Everolimus?

Everolimus has active ingredients of everolimus. eHealthMe is studying from 16,228 Everolimus users. Check the latest studies of Everolimus.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 04, 2026

13 people who take Everolimus and Pentacarinat together, and have interactions are studied.

Everolimus and Pentacarinat drug interactions.

What are the common drug interactions of Everolimus and Pentacarinat, by gender? *:

female:

Immunosuppressant drug level increased
Anaemia (lack of blood)
Epstein-barr virus associated lymphoma (epstein-barr virus associated tumour)
Renal failure (kidney dysfunction)
Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)

male:

Neutropenia (an abnormally low number of neutrophils)
Stenotrophomonas infection
Hypotension (abnormally low blood pressure)
Shunt occlusion (blockage of shunt)
Hyperthermia (body temperature greatly above normal)
Inflammation
Lymphocele (a collection of lymphatic fluid within the body not bordered by epithelial lining)
Transplant rejection (a transplant material is not worked)
Impaired healing
Renal impairment (severely reduced kidney function)

What are the common drug interactions of Everolimus and Pentacarinat, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Graft loss (graft failure)
Hypotension (abnormally low blood pressure)
Shunt occlusion (blockage of shunt)

20-29:

Anaemia (lack of blood)
Epstein-barr virus associated lymphoma (epstein-barr virus associated tumour)
Renal failure (kidney dysfunction)
Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
Immunosuppressant drug level increased

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Neutropenia (an abnormally low number of neutrophils)
Stenotrophomonas infection
Hyperthermia (body temperature greatly above normal)
Inflammation
Lymphocele (a collection of lymphatic fluid within the body not bordered by epithelial lining)
Transplant rejection (a transplant material is not worked)
Impaired healing
Renal impairment (severely reduced kidney function)
Renal lymphocele (a collection of lymphatic fluid within kidney)

What are the existing conditions these people have? *

Lung Transplant Rejection (failure of lung transplant): 7 people, 53.85%
Rickets (softening of bones): 1 person, 7.69%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%
Asthma: 1 person, 7.69%
Anaemia (lack of blood): 1 person, 7.69%
Aggression: 1 person, 7.69%
Acidosis (build-up of carbon dioxide in the blood): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Everolimus and Pentacarinat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously